TriSalus Life Sciences (TLSI) Competitors

Iradimed (NASDAQ:IRMD) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

Does the MarketBeat Community prefer IRMD or TLSI?

Iradimed received 247 more outperform votes than TriSalus Life Sciences when rated by MarketBeat users. However, 100.00% of users gave TriSalus Life Sciences an outperform vote while only 65.58% of users gave Iradimed an outperform vote.

Company	Underperform	Outperform
Iradimed	Outperform Votes 261 65.58%	Underperform Votes 137 34.42%
TriSalus Life Sciences	Outperform Votes 14 100.00%	Underperform Votes No Votes

Do analysts prefer IRMD or TLSI?

Iradimed presently has a consensus price target of $72.00, suggesting a potential upside of 19.98%. TriSalus Life Sciences has a consensus price target of $10.75, suggesting a potential upside of 104.76%. Given TriSalus Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe TriSalus Life Sciences is more favorable than Iradimed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iradimed	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
TriSalus Life Sciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25

Is IRMD or TLSI more profitable?

Iradimed has a net margin of 26.26% compared to TriSalus Life Sciences' net margin of -206.24%. Iradimed's return on equity of 24.12% beat TriSalus Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iradimed	26.26%	24.12%	21.20%
TriSalus Life Sciences	-206.24%	N/A	-236.83%

Does the media favor IRMD or TLSI?

In the previous week, TriSalus Life Sciences had 7 more articles in the media than Iradimed. MarketBeat recorded 10 mentions for TriSalus Life Sciences and 3 mentions for Iradimed. Iradimed's average media sentiment score of 1.81 beat TriSalus Life Sciences' score of 1.22 indicating that Iradimed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iradimed	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
TriSalus Life Sciences	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has better earnings and valuation, IRMD or TLSI?

Iradimed has higher revenue and earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Iradimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iradimed	$75.15M	10.15	$19.23M	$1.55	38.72
TriSalus Life Sciences	$32.14M	6.18	-$59.04M	-$1.12	-4.69

Which has more volatility and risk, IRMD or TLSI?

Iradimed has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500.

Do insiders and institutionals have more ownership in IRMD or TLSI?

92.3% of Iradimed shares are held by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are held by institutional investors. 36.8% of Iradimed shares are held by insiders. Comparatively, 27.5% of TriSalus Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Iradimed beats TriSalus Life Sciences on 13 of the 19 factors compared between the two stocks.